Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine.
We have developed a novel approach to cancer immunotherapy-an autologous whole-cell vaccine modified with the hapten dinitrophenyl (DNP). This approach elicits significant inflammatory responses in metastatic sites and some objective tumor responses. Post-surgical adjuvant immunotherapy with DNP-modified melanoma vaccine in a setting of micrometastatic disease produces significant survival prolongation in stage III melanoma patients. Histologically, the inflammatory responses of the tumor consist of infiltration by lymphocytes, the majority of which are CD8+, HLA-DR+ T cells. T cells from these lesions tend to have mRNA for interferon gamma. T cell receptor analysis suggests that the tumor-infiltrating T cells are clonally expanded. DNP-modified vaccine also induces T cells in the peripheral blood, which respond to DNP-modified autologous cells in a hapten-specific, MHC-restricted manner. Moreover, a T cell line generated from these lymphocytes responded to only a single HPLC fraction of MHC-associated, DNP-modified tumor peptides. Since inflammatory responses in metastases were not consistently associated with dramatic tumor regression, we considered the possibility of immunosuppression at the tumor site. We found that mRNA for the anti-inflammatory cytokine, interleukin-10 (IL-10) is expressed in most metastatic melanoma tissues and subsequently demonstrated that IL-10 protein is produced by melanoma cells. Thus the efficacy of DNP vaccine could be further enhanced by inhibition of IL-10 production or binding. Finally, we expect these results obtained with melanoma to be applicable to other human cancers.
Sato
T
T
Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107-5099, USA. t_sato@lac.jci.tju.edu
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D004136:Dinitrobenzenes / Q000276:immunology*; D018572:Disease-Free Survival; D006241:Haptens / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D051379:Mice; D018074:Vaccines, Conjugate / Q000276:immunology / Q000627:therapeutic use
D019496:Cancer Vaccines; D004136:Dinitrobenzenes; D006241:Haptens; D018074:Vaccines, Conjugate